$1.10
▲ +1.4% Today
as of Sep 4, 16:51 ET
Last 30 days
Recent Press Releases & News
Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript
Lineage Cell Therapeutics Q2 Earnings Call Highlights
Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary
Overview
52-week range
$1.00
$2.09
9% of range
Avg surprise (last 3)
0.0%
Avg reaction (last 2)
-0.3%
50% positive
Latest IV / EM
148%
EM ±23.1% · $1 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.03 | — | — | — | — | financials |
| Tue May 12, 2026 | Mar/2026 | $-0.03 | $-0.02 | -50.0% | -50.0% | +1.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.13 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.01 | $-0.02 | +50.0% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.02 | $-0.02 | 0.0% | — | -2.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.02 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.03 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.04 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.04 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.03 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.03 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $2M | — | $4M | $3M | $2M | — | $4M |
| Cost of revenue | — | — | — | — | — | $36,000 | — | $38,000 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-9M | $-8M | — | $-4M | $-20M | $-7M | — | $-4M |
| Net income | $1M | $-5M | — | $-30M | $-30M | $-4M | — | $-3M |
| EPS (diluted) | $-0.03 | $-0.03 | — | $-0.13 | $-0.13 | $-0.02 | — | $-0.02 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $37M | $36M | $41M | $40M | $42M | $48M | $46M | $28M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $53M | $56M | $59M | $42M | $44M | $50M | $51M | $34M |
| Total assets | $106M | $110M | $113M | $90M | $91M | $112M | $113M | $97M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $46M | $57M | $69M | $69M | $44M | $34M | $36M | $32M |
| Total equity | $61M | $53M | $45M | $22M | $47M | $78M | $78M | $65M |